TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
Abstract
TP53 truncating mutations are common in human tumors and are thought to give rise to p53-null alleles. Here, we show that TP53 exon-6 truncating mutations occur at higher than expected frequencies and produce proteins that lack canonical p53 tumor suppressor activities but promote cancer cell proliferation, survival, and metastasis. Functionally and molecularly, these p53 mutants resemble the naturally occurring alternative p53 splice variant, p53-psi. Accordingly, these mutants can localize to mitochondria where they promote tumor phenotypes by binding and activating the mitochondria inner pore permeability regulator, Cyclophilin D (CypD). Together, our studies reveal that TP53 exon-6 truncating mutations, contrary to current beliefs, act beyond p53 loss to promote tumorigenesis, and could inform the development of strategies to target cancers driven by these prevalent mutations.
Data availability
-
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaPublicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive Molecular Portraits of Invasive Lobular Breast CancerPublicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive molecular characterization of human colon and rectal cancer.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Genomic and molecular characterization of esophageal squamous cell carcinoma.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
The somatic genomic landscape of glioblastoma.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive genomic characterization of head and neck squamous cell carcinomas.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive molecular profiling of lung adenocarcinomaPublicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive genomic characterization of squamous cell lung cancers.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Integrated genomic analyses of ovarian carcinoma.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
The Molecular Taxonomy of Primary Prostate Cancer.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive genomic profiles of small cell lung cancer.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Comprehensive molecular characterization of gastric adenocarcinoma.Publicly available at the cBioPortal (http://www.cbioportal.org) .
-
Integrated genomic characterization of endometrial carcinoma.Publicly available at the cBioPortal (http://www.cbioportal.org) .
Article and author information
Author details
Funding
National Cancer Institute (NCI P01 CA129243-06)
- Raffaella Sordella
- Marc Ladanyi
- Scott W Lowe
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments were performed in accordance with National Research Council's Guide for the Care and Use of Laboratory Animals. Protocols were approved by the Cold Spring Harbor Laboratory Animal Care and Use Committee (933922-1 Development of mouse models to study human lung cancer - integrated protocols).
Copyright
© 2016, Sordella et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,131
- views
-
- 892
- downloads
-
- 48
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
In the realm of cancer immunotherapy, the meticulous selection of neoantigens plays a fundamental role in enhancing personalized treatments. Traditionally, this selection process has heavily relied on predicting the binding of peptides to human leukocyte antigens (pHLA). Nevertheless, this approach often overlooks the dynamic interaction between tumor cells and the immune system. In response to this limitation, we have developed an innovative prediction algorithm rooted in machine learning, integrating T cell receptor β chain (TCRβ) profiling data from colorectal cancer (CRC) patients for a more precise neoantigen prioritization. TCRβ sequencing was conducted to profile the TCR repertoire of tumor-infiltrating lymphocytes (TILs) from 28 CRC patients. The data unveiled both intra-tumor and inter-patient heterogeneity in the TCRβ repertoires of CRC patients, likely resulting from the stochastic utilization of V and J segments in response to neoantigens. Our novel combined model integrates pHLA binding information with pHLA-TCR binding to prioritize neoantigens, resulting in heightened specificity and sensitivity compared to models using individual features alone. The efficacy of our proposed model was corroborated through ELISpot assays on long peptides, performed on four CRC patients. These assays demonstrated that neoantigen candidates prioritized by our combined model outperformed predictions made by the established tool NetMHCpan. This comprehensive assessment underscores the significance of integrating pHLA binding with pHLA-TCR binding analysis for more effective immunotherapeutic strategies.